January 10, 2018 / 2:48 PM / in 12 minutes BRIEF-Vertex Receives EU Approval For Orkambi Reuters Staff 1 Min Read 
Jan 10 (Reuters) - Vertex Pharmaceuticals Inc: 
* VERTEX RECEIVES EU APPROVAL FOR ORKAMBIÂ® (LUMACAFTOR/IVACAFTOR) IN CHILDREN WITH CYSTIC FIBROSIS AGES 6-11 WITH TWO COPIES OF THE F508DEL MUTATION Source text for Eikon: Further company coverage: